ir.sutrobio.comInvestor Relations :: Sutro Biopharma, Inc. (STRO)
ir.sutrobio.com Profile
Ir.sutrobio.com is a subdomain of sutrobio.com, which was created on 2008-02-01,making it 16 years ago.
Description：Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients....
Discover ir.sutrobio.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.sutrobio.com Information
| HomePage size: 88.968 KB |
| Page Load Time: 0.40976 Seconds |
| Website IP Address: 50.18.211.61 |
ir.sutrobio.com Similar Website
| Masonite International Corp. - Investor Relations - Investor Relations |
| Block, Inc. (SQ) Investor Relations - Investor Relations |
| Gen Investor Relations - Investor Relations |
| MindChamps PreSchool Limited - Investor Relations: Investor Relations |
| Home - Ayala Land Investor Relations : Ayala Land Investor Relations |
| Universal Technical Institute's Investor Relations - UTI Investor Relations |
| Ameriprise Financial Investor Relations | Investor Relations |
| Meridian Bank Investor Relations - Meridian Bank Investor Relations |
| Armstrong World Industries Investor Relations | Armstrong Flooring Investor Relations |
| Investor Relations | PDL BioPharma, Inc. |
| Walmart Investor Relations - Investor Relations |
| Alphabet Investor Relations - Investor Relations - Alphabet |
ir.sutrobio.com PopUrls
| Sutro Biopharma, Inc. (STRO) https://ir.sutrobio.com/ |
| Financial Information https://ir.sutrobio.com/financial-information |
| Corporate Governance https://ir.sutrobio.com/corporate-governance |
| News & Events https://ir.sutrobio.com/news-events |
| Quote :: Sutro Biopharma, Inc. (STRO) https://ir.sutrobio.com/stock-data |
| Stock Quote https://ir.sutrobio.com/stock-data/quote |
| Company Information https://ir.sutrobio.com/company-information |
| Contacts :: Sutro Biopharma, Inc. (STRO) https://ir.sutrobio.com/company-information/contacts |
| SEC Filings https://ir.sutrobio.com/sec-filings |
| Company Information :: Sutro Biopharma, Inc. (STRO) https://ir.sutrobio.com/company-information/overview |
| Sutro Biopharma Reports Full Year 2023 Financial Results, Business ... https://ir.sutrobio.com/news-events/news-releases/detail/190/sutro-biopharma-reports-full-year-2023-financial-results |
| Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business ... https://ir.sutrobio.com/news-events/news-releases/detail/152/sutro-biopharma-reports-second-quarter-2022-financial |
| Sutro Biopharma Achieves “First in Human” Milestone in Cytokine ... https://ir.sutrobio.com/news-events/news-releases/detail/150/sutro-biopharma-achieves-first-in-human-milestone-in-cytokine-derivatives-collaboration-w |
| Sutro Biopharma Strengthens Leadership Through Management Promotions ... https://ir.sutrobio.com/news-events/news-releases/detail/112/sutro-biopharma-strengthens-leadership-through-management-promotions-and-expansion-of-cli |
| Quarterly Reports :: Sutro Biopharma, Inc. (STRO) https://ir.sutrobio.com/sec-filings/quarterly-reports |
ir.sutrobio.com Httpheader
| Date: Mon, 13 May 2024 05:57:06 GMT |
| Server: Apache |
| X-Frame-Options: SAMEORIGIN |
| Expires: Thu, 19 Nov 1981 08:52:00 GMT |
| Cache-Control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0 |
| Pragma: no-cache |
| Vary: Accept-Encoding |
| Transfer-Encoding: chunked |
| Content-Type: text/html; charset=UTF-8 |
ir.sutrobio.com Meta Info
| charset="utf-8"/ |
| content="IE=edge" http-equiv="X-UA-Compatible"/ |
| content="https://ir.sutrobio.com" property="og:url"/ |
| content="Sutro Biopharma, Inc." property="og:site_name"/ |
| content="Investor Relations" property="og:title"/ |
| content="website" property="og:type"/ |
| content="https://d1io3yog0oux5.cloudfront.net/_0b4424daecfce49749dd7a070fa9fad9/sutrobio/db/874/6994/social_image_resized.jpg" property="og:image"/ |
| content="summary_large_image" name="twitter:card"/ |
| content="Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology,…" property="og:description"/ |
| content="Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology,…" name="description"/ |
| content="WordPress 5.4.2" name="generator" |
| content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" name="viewport" |
| content="Powered by WPBakery Page Builder - drag and drop page builder for WordPress." name="generator" |
| content="Powered by Slider Revolution 5.4.3 - responsive, Mobile-Friendly Slider Plugin for WordPress with comfortable drag and drop interface." name="generator" |
| content="https://www.sutrobio.com/wp-content/uploads/2020/03/cropped-sutro-icon-500x500-1-270x270.png" name="msapplication-TileImage" |
ir.sutrobio.com Ip Information
| Ip Country: United States |
| City Name: San Jose |
| Latitude: 37.1835 |
| Longitude: -121.7714 |
ir.sutrobio.com Html To Plain Text
Who We Are About Sutro Leadership Leadership Team Functional Leadership Team Board of Directors Scientific Advisory Board Clinical Advisory Board Collaborations Corporate Presentation Patients Clinical Trials REFRaME-O1 Patient Resources Commitment To Patients Compassionate Use Access Science Pipeline iADCs & Antibody Drug Conjugates XpressCF+® cGMP Facility Investors Overview News & Events Company Info Financial Info Stock Data SEC Filings Governance News News Releases Presentation & Publication Events Events Audio Replays Join Us The Way We Work Join Our Team DEIB Sustainability Internships Philanthropy Employee Engagement Contact Us Search Navigation About About Sutro Leadership Leadership Team Functional Leadership Team Board of Directors Scientific Advisory Board Clinical Advisory Board Collaborations Corporate Presentation Clinical Trials & CUA Clinical Trials REFRaME-O1 Patient Resources Commitment To Patients Compassionate Use Access Technology iADCs & Antibody-Drug Conjugates XpressCF+® cGMP Facility Investors Overview News & Events Company Info Financial Info Stock Data SEC Filings Governance Pipeline News News Releases Clinical / Scientific Presentation & Publication Highlights Events Events Audio Replays Careers, Culture & DEIB The Way We Work Join Our Team DEIB DEIB Newsletter Internships Sutroites Volunteer Current Volunteer Newsletter Contact Us Close Investor Relations Investors Investors Overview News & Events Overview News Releases Events & Audio Replays Email Alerts Company Info Overview Management Team Functional Leadership Team Presentations Contacts FAQ Financial Info Overview Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote Charts Historical Data Analysts Coverage SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Latest News Apr 30, 2024 Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial View Press Release Apr 2, 2024 Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering Apr 2, 2024 Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors View All News Latest Presentation Corporate Presentation View Presentation Upcoming Event Jun 6, 2024 9:00 am PDT 2024 Annual Meeting of Stockholders Add to Calendar View All Latest Financial Results FY 2023 Fiscal Year Ended Dec 31, 2023 Earnings Release PDF HTML 10-K Filing PDF HTML XBRL ZIP XLS HTML Latest Annual Filing For Fiscal Year Ending Dec 31, 2023 Report Links Annual Report Document Links View 10-K Sign Up For Email Alerts Receive updates straight into your inbox Sign up today Company Overview Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com . View Management Team View Board of Directors Investor Contact Information Company Sutro Biopharma, Inc. 111 Oyster Point Blvd South San Francisco, CA 94080 Investor Relations and Media Contact Sutro Biopharma Emily White Investor Relations and Communications Advisor T: 650-823-7681 ewhite@sutrobio.com Email Alerts Contacts RSS News Feed Sutro Biopharma 111 Oyster Point Blvd South San Francisco, CA 94080 Phone: 650-881-6500 Fax: 650-553-9659 Google Map Contact Us General Inquires: general@sutrobio.com Business Inquires: busdev@sutrobio.com Investor Relations Inquires: IR@sutrobio.com Careers: jobs@sutrobio.com Copyright © 2024 Sutro Biopharma, Inc. South San Francisco, California, U.S.A. Privacy Policy Follow Follow Follow Follow Sign Up for Email Alerts Market Data copyright © 2024 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT =Real-Time, EOD =End of Day, PD =Previous Day. Market Data powered by QuoteMedia . Terms of Use...
ir.sutrobio.com Whois
Domain Name: SUTROBIO.COM Registry Domain ID: 1393005726_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2024-02-02T16:45:45Z Creation Date: 2008-02-01T21:26:47Z Registry Expiry Date: 2025-02-01T21:26:47Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS23.DOMAINCONTROL.COM Name Server: NS24.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T16:02:58Z <<<